New drug aims to soften skin in rare autoimmune disease
NCT ID NCT05198557
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called MT-0551 against a placebo in 80 adults with systemic sclerosis, a disease that causes skin thickening and can affect internal organs. The main goal is to see if the drug reduces skin hardness over 26 weeks. Researchers will also check lung function and safety. Participants must have moderate skin thickening and no severe lung complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, 920-8641, Japan
-
St. Marianna University Hospital
Kawasaki-shi, Kanagawa, 216-8511, Japan
-
The University of Tokyo Hospital
Bunkyo-ku, Tokyo, 113-8655, Japan
-
University of Fukui Hospital
Yoshida-gun, Fukui, 910-1193, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Blood particles may reveal hidden clues to scleroderma complications
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Finger injections aim to loosen stiff hands in scleroderma
- Continued anifrolumab treatment studied for lupus and related diseases
- Blood thinner may stop autoimmune disease before it starts